Comparative assessment of trial-level surrogacy measures for candidate time-to-event surrogate endpoints in clinical trials

Computational Statistics and Data Analysis

Volumn 55, Issue 9, 2011, Pages 2748-2757

  Shi, Qian ^a   Renfro, Lindsay A ^b   Bot, Brian M ^a   Burzykowski, Tomasz ^c,d   Buyse, Marc ^c,d   Sargent, Daniel J ^a  

^a MAYO CLINIC   (United States)

^b BAYLOR UNIVERSITY   (United States)

^c HASSELT UNIVERSITY   (Belgium)

^d INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

Author keywords

Clinical trials; Meta analysis; Survival analysis; Trial level surrogacy

Indexed keywords

CLINICAL TRIAL; COLON CANCER; COMPARATIVE ASSESSMENT; CORRELATION COEFFICIENT; ESTIMATION PERFORMANCE; INDIVIDUAL PATIENT DATA; KEY FACTORS; LARGE SCALE SIMULATIONS; META-ANALYSIS; MODEL-BASED; R SQUARE; SURVIVAL ANALYSIS; SYSTEMATIC ASSESSMENT; TREATMENT EFFECTS; TRIAL-LEVEL SURROGACY;

COMPUTATIONAL EFFICIENCY; ESTIMATION; EXPERIMENTS; HOSPITAL DATA PROCESSING; SEEBECK EFFECT;

RATING;

EID: 79956109483     PISSN: 01679473     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.csda.2011.03.014     Document Type: Article

References (17)

1. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework Clinical Pharmacology and Therapeutics 69 3 2001 89 95
2. T. Burzykowski, G. Molenberghs, and M. Buyse The Evaluation of Surrogate Endpoints 2005 Springer
3. T. Burzykowski, G. Molenberghs, M. Buyse, H. Geys, and D. Renard Validation of surrogate end points in multiple randomized clinical trials with failure time end points Applied Statistics 50 4 2001 405 422
4. M. Buyse, and G. Molenberghs Criteria for the validation of surrogate endpoints in randomized experiments Biometrics 54 3 1998 1014 1029 (Pubitemid 28429294)
5. M. Buyse, G. Molenberghs, T. Burzykowski, D. Renard, and H. Geys The validation of surrogate endpoints in meta-analyses of randomized experiments Biostatistics 1 1 2000 49 67
6. D.G. Clayton A model for association in bivariate life tables and its application in epidemiological studies of familial tendency in chronic disease incidence Biometrika 65 1978 141 151 (Pubitemid 8308396)
7. Cowles, M.K., 2004. Evaluating surrogate endpoints for clinical trials: a Bayesian approach. Tech. Rep. Department of Statistics and Actuarial Science. University of Iowa.
8. M.J. Daniels, and M.D. Hughes Meta-analysis for the evaluation of potential surrogate markers Statistics in Medicine 16 1997 1965 1982 (Pubitemid 27397267)
9. E. Green, G. Yothers, and D.J. Sargent Surrogate endpoint validation: statistical elegance versus clinical relevance Statistical Methods in Medical Research 17 5 2008 477 486 http://dx.doi.org/10.1177/0962280207081863
10. M.N. Lassere The biomarker-surrogacy evaluation schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints Statistical Methods in Medical Research 17 3 2008 303 340 http://dx.doi.org/10.1177/0962280207082719
11. G. Molenberghs, M. Buyse, H. Geys, D. Renard, T. Burzykowski, and A. Alonso Statistical challenges in the evaluation of surrogate endpoints in randomized trials Controlled Clinical Trials 23 6 2002 607 625 (Pubitemid 36005472)
12. J. Nocedal, and S.J. Wright Numerical Optimization 1999 Springer
13. R.L. Prentice Surrogate endpoints in clinical trials: definition and operational criteria Statistics in Medicine 8 1989 431 440 (Pubitemid 19105891)
14. D.J. Sargent, S. Patiyil, G. Yothers, D.G. Haller, R. Gray, J. Benedetti, M. Buyse, R. Labianca, J.F. Seitz, C.J. O'Callaghan, G. Francini, A. Grothey, M. O'Connell, P.J. Catalano, D. Kerr, E. Green, H.S. Wieand, R.M. Goldberg, and A. de Gramont End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the accent group Journal of Clinical Oncology 25 29 2007 4569 4574 Group A.C.C.E.N.T. (Pubitemid 350035314)
15. D.J. Sargent, H.S. Wieand, D.G. Haller, R. Gray, J.K. Benedetti, M. Buyse, R. Labianca, J.F. Seitz, C.J. O'Callaghan, G. Francini, A. Grothey, M. O'Connell, P.J. Catalano, C.D. Blanke, D. Kerr, E. Green, N. Wolmark, T. Andre, R.M. Goldberg, and A.D. Gramont Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials Journal of Clinical Oncology 23 34 2005 8664 8670 http://dx.doi.org/10.1200/JCO.2005.01.6071 (Pubitemid 46211509)
16. Q. Shi, and D.J. Sargent Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials International Journal of Clinical Oncology 14 2 2009 102 111 http://dx.doi.org/10.1007/s10147-009-0885-4
17. C. Weir, and R.J. Walley Statistical evaluation of biomarkers as surrogate endpoints: a literature review Statistics in Medicine 25 2006 183 203 (Pubitemid 43141502)